Precipio, Inc. (PRPO)
USD 5.56
(-3.81%)
USD 5.56
(-3.81%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 15.19 Million USD | 61.46% |
| 2022 | 9.41 Million USD | 6.36% |
| 2021 | 8.84 Million USD | 45.26% |
| 2020 | 6.09 Million USD | 94.82% |
| 2019 | 3.12 Million USD | 9.18% |
| 2018 | 2.86 Million USD | 66.22% |
| 2017 | 1.72 Million USD | 10.66% |
| 2016 | 1.55 Million USD | -5.81% |
| 2015 | 1.65 Million USD | -93.9% |
| 2014 | 27.08 Million USD | -1.67% |
| 2013 | 27.54 Million USD | -12.5% |
| 2012 | 31.48 Million USD | -1.54% |
| 2011 | 31.97 Million USD | 59.47% |
| 2010 | 20.04 Million USD | -8.97% |
| 2009 | 22.02 Million USD | -8.21% |
| 2008 | 23.99 Million USD | 3.53% |
| 2007 | 23.17 Million USD | -1.02% |
| 2006 | 23.41 Million USD | -9.34% |
| 2005 | 25.82 Million USD | -23.56% |
| 2004 | 33.78 Million USD | -0.23% |
| 2003 | 33.86 Million USD | -9.82% |
| 2002 | 37.55 Million USD | -2.37% |
| 2001 | 38.46 Million USD | 48.62% |
| 2000 | 25.88 Million USD | 12.36% |
| 1999 | 23.03 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.44 Million USD | 29.4% |
| 2024 Q1 | 3.43 Million USD | -20.72% |
| 2023 Q1 | 2.81 Million USD | 17.82% |
| 2023 FY | 15.19 Million USD | 61.46% |
| 2023 Q4 | 4.32 Million USD | 15.81% |
| 2023 Q3 | 3.73 Million USD | 5.8% |
| 2023 Q2 | 3.53 Million USD | 25.42% |
| 2022 Q2 | 2.35 Million USD | -3.6% |
| 2022 FY | 9.41 Million USD | 6.36% |
| 2022 Q3 | 2.21 Million USD | -6.1% |
| 2022 Q4 | 2.39 Million USD | 7.95% |
| 2022 Q1 | 2.44 Million USD | 0.49% |
| 2021 FY | 8.84 Million USD | 45.26% |
| 2021 Q2 | 2.34 Million USD | 28.51% |
| 2021 Q3 | 2.24 Million USD | -4.18% |
| 2021 Q4 | 2.43 Million USD | 8.41% |
| 2021 Q1 | 1.82 Million USD | -6.03% |
| 2020 Q2 | 1.3 Million USD | 7.57% |
| 2020 FY | 6.09 Million USD | 94.82% |
| 2020 Q3 | 1.62 Million USD | 24.39% |
| 2020 Q4 | 1.94 Million USD | 19.3% |
| 2020 Q1 | 1.21 Million USD | 76.74% |
| 2019 FY | 3.12 Million USD | 9.18% |
| 2019 Q1 | 713 Thousand USD | 4.09% |
| 2019 Q2 | 942 Thousand USD | 32.12% |
| 2019 Q3 | 784 Thousand USD | -16.77% |
| 2019 Q4 | 688 Thousand USD | -12.24% |
| 2018 Q1 | 712 Thousand USD | -24.66% |
| 2018 FY | 2.86 Million USD | 66.22% |
| 2018 Q4 | 685 Thousand USD | 5.38% |
| 2018 Q3 | 650 Thousand USD | -20.44% |
| 2018 Q2 | 817 Thousand USD | 14.75% |
| 2017 FY | 1.72 Million USD | 10.66% |
| 2017 Q1 | 658 Thousand USD | 83.29% |
| 2017 Q2 | 260 Thousand USD | -60.49% |
| 2017 Q4 | 945 Thousand USD | 250.0% |
| 2017 Q3 | 270 Thousand USD | 3.85% |
| 2016 Q2 | 505 Thousand USD | 113.98% |
| 2016 Q4 | 359 Thousand USD | -21.44% |
| 2016 FY | 1.55 Million USD | -5.81% |
| 2016 Q1 | 236 Thousand USD | 101.96% |
| 2016 Q3 | 457 Thousand USD | -9.5% |
| 2015 Q3 | 3.96 Million USD | -43.75% |
| 2015 FY | 1.65 Million USD | -93.9% |
| 2015 Q2 | 7.04 Million USD | 8.09% |
| 2015 Q1 | 6.51 Million USD | -15.37% |
| 2015 Q4 | -12.01 Million USD | -403.46% |
| 2014 Q2 | 6.76 Million USD | 8.21% |
| 2014 FY | 27.08 Million USD | -1.67% |
| 2014 Q1 | 6.25 Million USD | 0.53% |
| 2014 Q4 | 7.69 Million USD | 20.78% |
| 2014 Q3 | 6.37 Million USD | -5.8% |
| 2013 FY | 27.54 Million USD | -12.5% |
| 2013 Q4 | 6.21 Million USD | -6.44% |
| 2013 Q2 | 7.3 Million USD | -0.92% |
| 2013 Q3 | 6.64 Million USD | -9.03% |
| 2013 Q1 | 7.37 Million USD | 1.12% |
| 2012 Q3 | 7.88 Million USD | -13.24% |
| 2012 Q4 | 7.29 Million USD | -7.57% |
| 2012 Q2 | 9.09 Million USD | 26.19% |
| 2012 Q1 | 7.2 Million USD | -15.93% |
| 2012 FY | 31.48 Million USD | -1.54% |
| 2011 Q4 | 8.57 Million USD | 3.85% |
| 2011 Q3 | 8.25 Million USD | 7.64% |
| 2011 Q2 | 7.66 Million USD | 2.5% |
| 2011 Q1 | 7.48 Million USD | 46.9% |
| 2011 FY | 31.97 Million USD | 59.47% |
| 2010 Q3 | 4.41 Million USD | -13.27% |
| 2010 Q4 | 5.09 Million USD | 15.23% |
| 2010 Q2 | 5.09 Million USD | -6.38% |
| 2010 FY | 20.04 Million USD | -8.97% |
| 2010 Q1 | 5.44 Million USD | -16.47% |
| 2009 FY | 22.02 Million USD | -8.21% |
| 2009 Q1 | 4.98 Million USD | -18.53% |
| 2009 Q4 | 6.51 Million USD | 29.11% |
| 2009 Q3 | 5.04 Million USD | -7.8% |
| 2009 Q2 | 5.47 Million USD | 9.7% |
| 2008 Q2 | 6.24 Million USD | -0.13% |
| 2008 Q1 | 6.25 Million USD | -4.24% |
| 2008 Q3 | 5.36 Million USD | -14.07% |
| 2008 Q4 | 6.12 Million USD | 14.1% |
| 2008 FY | 23.99 Million USD | 3.53% |
| 2007 Q3 | 5.15 Million USD | -17.87% |
| 2007 Q1 | 5.22 Million USD | -10.12% |
| 2007 FY | 23.17 Million USD | -1.02% |
| 2007 Q4 | 6.53 Million USD | 26.79% |
| 2007 Q2 | 6.27 Million USD | 20.11% |
| 2006 Q4 | 5.81 Million USD | 18.11% |
| 2006 Q2 | 6.18 Million USD | -4.74% |
| 2006 Q3 | 4.91 Million USD | -20.52% |
| 2006 Q1 | 6.49 Million USD | 206.9% |
| 2006 FY | 23.41 Million USD | -9.34% |
| 2005 FY | 25.82 Million USD | -23.56% |
| 2005 Q2 | 7.63 Million USD | 3.53% |
| 2005 Q3 | 8.7 Million USD | 14.06% |
| 2005 Q4 | 2.11 Million USD | -75.68% |
| 2005 Q1 | 7.37 Million USD | -7.32% |
| 2004 Q2 | 9.01 Million USD | 4.43% |
| 2004 Q3 | 8.19 Million USD | -9.07% |
| 2004 Q4 | 7.95 Million USD | -2.92% |
| 2004 FY | 33.78 Million USD | -0.23% |
| 2004 Q1 | 8.62 Million USD | 3.4% |
| 2003 Q2 | 8.48 Million USD | -10.77% |
| 2003 Q3 | 7.53 Million USD | -11.13% |
| 2003 Q4 | 8.34 Million USD | 10.72% |
| 2003 Q1 | 9.5 Million USD | 3.18% |
| 2003 FY | 33.86 Million USD | -9.82% |
| 2002 Q2 | 9.42 Million USD | -4.14% |
| 2002 Q4 | 9.21 Million USD | 1.38% |
| 2002 Q1 | 9.83 Million USD | -8.45% |
| 2002 FY | 37.55 Million USD | -2.37% |
| 2002 Q3 | 9.08 Million USD | -3.58% |
| 2001 Q4 | 10.73 Million USD | 4.72% |
| 2001 FY | 38.46 Million USD | 48.62% |
| 2001 Q1 | 7.93 Million USD | 11.73% |
| 2001 Q2 | 9.54 Million USD | 20.37% |
| 2001 Q3 | 10.25 Million USD | 7.43% |
| 2000 FY | 25.88 Million USD | 12.36% |
| 2000 Q1 | 6.94 Million USD | 0.0% |
| 2000 Q2 | 5.59 Million USD | -19.46% |
| 2000 Q3 | 6.24 Million USD | 11.74% |
| 2000 Q4 | 7.09 Million USD | 13.57% |
| 1999 FY | 23.03 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bionano Genomics, Inc. | 36.11 Million USD | 57.922% |
| Prenetics Global Limited | 21.74 Million USD | 30.105% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 66.808% |
| CareDx, Inc | 280.32 Million USD | 94.579% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.392% |
| Exagen Inc. | 52.54 Million USD | 71.08% |
| Inotiv, Inc. | 572.42 Million USD | 97.345% |
| Guardant Health, Inc. | 563.94 Million USD | 97.305% |
| Biodesix, Inc. | 49.08 Million USD | 69.041% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -55.535% |
| iSpecimen Inc. | 9.92 Million USD | -53.069% |
| Natera, Inc. | 1.08 Billion USD | 98.596% |
| Aspira Women's Health Inc. | 9.15 Million USD | -66.015% |
| Standard BioTools Inc. | 106.34 Million USD | 85.709% |
| 23andMe Holding Co. | 219.63 Million USD | 93.081% |
| Castle Biosciences, Inc. | 219.78 Million USD | 93.086% |
| Personalis, Inc. | 73.48 Million USD | 79.318% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 51.368% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -13.687% |
| OpGen, Inc. | 3.41 Million USD | -344.575% |
| T2 Biosystems, Inc. | 7.19 Million USD | -111.275% |
| Myriad Genetics, Inc. | 678.4 Million USD | 97.76% |
| ICON Public Limited Company | 8.12 Billion USD | 99.813% |
| NeoGenomics, Inc. | 591.64 Million USD | 97.431% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 66.808% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.585% |
| RadNet, Inc. | 1.61 Billion USD | 99.06% |
| MDxHealth SA | 70.19 Million USD | 78.35% |
| Psychemedics Corporation | 22.09 Million USD | 31.229% |
| Illumina, Inc. | 4.5 Billion USD | 99.663% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 95.144% |
| DarioHealth Corp. | 20.35 Million USD | 25.329% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 94.745% |
| Sera Prognostics, Inc. | 306 Thousand USD | -4866.34% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| OPKO Health, Inc. | 863.49 Million USD | 98.24% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.194% |
| Neogen Corporation | 924.22 Million USD | 98.356% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -388.37% |
| Prenetics Global Limited | 21.74 Million USD | 30.105% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -1597.081% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -500.079% |
| Trinity Biotech plc | 56.83 Million USD | 73.26% |
| Neuronetics, Inc. | 71.34 Million USD | 78.7% |
| Sotera Health Company | 1.04 Billion USD | 98.552% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -500.079% |